Diabetic corneal alterations, such as delayed epithelial wound healing, edema, recurrent erosions, neuropathy/loss of sensitivity, and tear film changes are frequent but underdiagnosed complications of both type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus. The disease affects corneal epithelium, corneal nerves, tear film, and to a lesser extent, endothelium, and also conjunctiva. These abnormalities may appear or become exacerbated following trauma, as well as various surgeries including retinal, cataract or refractive. The focus of the review is on mechanisms of diabetic corneal abnormalities, available animal, tissue and organ culture models, and emerging treatments. Changes of basement membrane structure and wound healing rates, the role of various proteinases, advanced glycation end products (AGEs), abnormal growth and motility factors (including opioid, epidermal, and hepatocyte growth factors) are analyzed. Experimental therapeutics under development, including topical naltrexone, insulin, inhibitors of aldose reductase, and AGEs, as well as emerging gene and cell therapies are discussed in detail.
Introduction
Diabetes mellitus is currently the leading cause of legal blindness in the working age adults worldwide. Diabetic retinopathy (DR) is a major and the most severe ocular complication of diabetes mellitus (Aiello et al., 1998) . DR is the leading cause of new blindness in persons 25 to 74 years of age in the United States, accounting for about 8000 new blindness cases each year (Aiello et al., 1998; Negi & Vernon, 2003) . Patients with insulin-dependent diabetes (type 1, IDDM) will develop DR in more than 90% of cases, and proliferative DR (PDR), in up to 50% of cases after 20 years of disease; patients with non-insulin-dependent diabetes (type 2, NIDDM) also frequently develop DR (Aiello et al., 1998; Klein, 2008; Negi & Vernon, 2003) . Overall, 43% of type 1 and 60% of type 2 diabetics lose vision within 5 years of the onset of PDR.
Diabetic eye disease is typically considered as a retinal microvascular disorder and is thus generally called diabetic retinopathy. Nonproliferative DR (NPDR) is associated with retinal ischemia, pericyte loss, capillary closure, retinal hemorrhages, microaneurysms, and macular edema. PDR is associated with intravitreal hemorrhages, optic disc or peripheral neovascularization, preretinal fibrovascular membranes, and vitreoretinal traction with retinal detachments (Yam & Kwok, 2007) . DR is mainly treated with tight blood glucose control that is more effective in IDDM and laser surgery [panretinal laser photocoagulation (PRP)], (Aiello et al., 1998; Henricsson, Nilsson, Janzon, & Groop, 1997; Negi & Vernon, 2003; Yam & Kwok, 2007) . Eyes with nonclearing vitreous hemorrhage are treated with vitrectomy followed by PRP (Aiello et al., 1998) . DR and/or PDR progression may be slowed down by treatment with steroids, somatostatin analogs, and antagonists of vascular endothelial growth factor (Dhoot & Avery, 2016; Jonas, 2007; Lang, 2007; Ljubimov, Boulton, Caballero, & Grant, 2008) . Results from animal models suggest that combination therapy may be the most promising future approach to PDR treatment (Dorrell, Aguilar, Scheppke, Barnett, & Friedlander, 2007; Jo et al., 2006; Kramerov et al., 2006) .
Given its major impact on vision, retinal disease in diabetes remains the primary concern of physicians. At the same time, other parts of the eye (e.g., iris, lens, optic nerve) also suffer from diabetic complications, although they are encountered in less than 30% of diabetic patients (Blum et al., 2007; Ducrey, 1996; Helbig, 2007; Murtha & Cavallerano, 2007; Nakamura, Kanamori, & Negi, 2005) . Corneal problems seem to be more frequent affecting up to 70% of examined diabetic patients (Abdelkader, Patel, McGhee, & Alany, 2011; Didenko, Smoliakova, Sorokin, & Egorov, 1999; Schultz, Van Horn, Peters, Klewin, & Schutten, 1981 ; VieiraPotter, Karamichos, & Lee, 2016) . However, these changes are rarely diagnosed (Herse, 1988; Wylegała, Moć ko, WoynaOrlewicz, Teper, & Orzhechowska-Wylegała, 2006) . Major attention is paid to the retina despite the proposed inclusion of ocular surface assessment during eye examination in diabetic patients (Aiello et al., 1998; Ben Osman et al., 1995; DeMill, Hussain, PopBusui, & Shtein, 2016) . Currently, 18% of corneas transplanted in the United States come from diabetic donors (Lass et al., 2015) , which may not be beneficial for recipients due to lasting epigenetic changes in these corneas. The present review will attempt at bridging this gap and presenting a comprehensive analysis of corneal diabetic complications. Earlier reviews on diabetic corneal disease focused primarily on clinical problems (Cisarik-Fredenburg, 2001; Kaji, 2005; Sánchez-Thorin, 1998 ). More recently, appropriate attention was given to the mechanisms of disease and available therapies (Bikbova, Oshitari, Tawada, & Yamamoto, 2012; CalvoMaroto, Perez-Cambrodí, Albarán-Diego, Pons, & Cerviño, 2014; Misra, Braatvedt, & Patel, 2016; Shih, Lam, & Tong, 2017; VieiraPotter et al., 2016) . This review provides recent updates in this rapidly developing field and analyzes in more detail the latest therapeutic candidates. Emphasis is also given to molecular events and mechanisms underlying this disease, which need to be understood in more detail in order to develop new effective treatments (Karamichos, 2015) .
General manifestations of diabetes in the cornea
Clinically observed corneal diabetic alterations include increased corneal thickness, epithelial defects, epithelial fragility and recurrent erosions, ulcers, edema, superficial punctate keratitis, delayed and incomplete wound repair, endothelial changes, and neuropathy exemplified by reduced corneal sensitivity (Bikbova et al., 2012; Cavallerano, 1992; Gekka et al., 2004; Herse, 1988; Malik et al., 2003; Módis et al., 2010; Negi & Vernon, 2003; Saini & Khandalavla, 1995; Saito et al., 2003; Shih et al., 2017; Su et al., 2008; Sánchez-Thorin, 1998; Vieira-Potter et al., 2016; Wylegała et al., 2006) . Diabetic corneal neuropathy, corneal autofluorescence [possibly due to the accumulation of advanced glycation end products (AGEs)], and epithelial fragility are all augmented in patients with DR (Chang, Hsu, Hu, & Chen, 1995; Janiec et al., 1995; Saini & Mittal, 1996a; Van Schaik et al., 1999; Bikbova et al., 2012; Calvo-Maroto, Perez-Cambrodi, Garcia-Lazaro, Ferrer-Blasco, & Cerviño, 2016; DeMill et al., 2016) . Diabetics often have low tear secretion and dry eye syndrome (Beckman, 2014; Cousen, Cackett, Bennett, Swa, & Dhillon, 2007; Inoue et al., 2001; Manaviat, Rashidi, Afkhami-Ardekani, & Shoja, 2008; Yoon, Im, & Seo, 2004) . Similar to diabetic retina, diabetic corneas are also affected by dyslipidemia with increased content of sphingosines and ceramides (Priyadarsini, Sarker-Nag, Allegood, Chalfant, & Karamichos, 2015; Priyadarsini, McKay et al., 2016) . Major changes in human and animal diabetic corneas are listed in Table 1 .
Epithelial abnormalities
Diabetic epithelial problems are often summarily referred to as diabetic keratopathy emphasizing the major impact on corneal epithelium. Signs of diabetic keratopathy include epithelial fragility, defects and recurrent erosions, non-healing ulcers, corneal edema due to altered epithelial barrier function, superficial punctate keratitis, abnormally slow and often incomplete wound healing, lower cell density especially in the basal layer, and increased susceptibility to injury (Ben Osman et al., 1995; Cavallerano, 1992; Gekka et al., 2004; Inoue et al., 2001; Ohashi, 1997; Quadrado, Popper, Morgado, Murta, & Van Best, 2006; Saini & Khandalavla, 1995; Sánchez-Thorin, 1998; Szalai et al., 2016; Vieira-Potter et al., 2016; Wylegała et al., 2006) . The data on the prevalence of diabetic keratopathy depending on the type of diabetes remain inconsistent and need to be revisited (Didenko et al., 1999; Schultz et al., 1981) . Women with poor glycemic control have a higher diabetic keratopathy incidence than men, especially with IDDM (up to 90%) (Schultz et al., 1981) .
It has been long suggested that diabetic keratopathy is a sign of peripheral neuropathy (Schultz, Peters, Sobocinski, Nassif, & Schultz, 1983) . This idea was substantiated by later findings of frequent association between corneal epithelial changes and manifestations of diabetic neuropathy (Bikbova, Oshitari, Baba, & Yamamoto, 2016; Didenko et al., 1999; Mocan, Durukan, Irkec, & Orhan, 2006) . At the same time, neurotrophic keratopathy is reportedly a rare event in diabetics (Lockwood, Hope-Ross, & Chell, 2006) . Moreover, direct structural and functional changes in the corneal epithelium were observed in diabetic patients and animals, which may not be related to neuropathy unless in severe disease (Rosenberg et al., 2000; Saghizadeh, Brown et al., 2001; Saghizadeh et al., 2005; Saghizadeh et al., 2011; Chikama, Wakuta, Liu, & Nishida, 2007; Quadrado et al., 2006) . Further, high glucose treatment mimicking the diabetic hyperglycemia has a fast and direct impact on the normal corneal epithelial cells and the epithelium of organ-cultured corneas decreasing cell adhesion and slowing down wound healing (Fujita, Morita, Takase, OhnoMatsui, & Mochizuki, 2003; Tomomatsu, Takamura, Kubo, & Akagi, 2009; Xu, Li, Ljubimov, & Yu, 2009; Yin & Yu, 2010) . Additional studies should elucidate the degree and molecular mechanisms of the relationship between diabetic keratopathy and neuropathy.
Corneal nerve changes
Decreased corneal sensitivity in diabetic patients was already recognized in the 1970's (Nielsen, 1978) . Since then, the first findings were corroborated many times. It is now well established that corneal sensitivity decrease is very common in diabetic patients and animals. Its degree correlates with the disease severity (Cousen et al., 2007; De Cillà et al., 2009; Rosenberg et al., 2000; Saito et al., 2003; Tavakoli, Kallinikos, Efron, Boulton, & Malik, 2007; Zhivov et al., 2013) , although the age factor should also be taken into account (Murphy, Patel, Kong, Ryder, & Marshall, 2010) . This symptom is related to abnormalities of corneal nerve structure and function in diabetes. Detailed examination including the use of in vivo confocal microscopy has revealed abnormalities in nerve fiber density, length and branch density, as well as increased nerve tortuosity and thickness in human diabetic corneas (De Cillà et al., 2009; Kallinikos, Berhanu, O'Donnell, Boulton, Efron, & Malik, 2004; Malik et al., 2003; Mocan et al., 2006; Rosenberg et al., 2000; Szalai et al., 2016) . These alterations may be worsened after laser photocoagulation in PDR (De Cillà et al., 2009) . In both diabetic patients and animal models, the most severe reduction in nerve fiber and branch density occurs in the sub-basal nerve plexus close to the corneal epithelium, possibly explaining the correlation between diabetic keratopathy and neuropathy (Cai, Zhu, Petroll, Koppaka, & Robertson, 2014; Davidson, Coppey, Kardon, & Yorek, 2014; De Cillà et al., 2009; He & Bazan, 2012; Stem et al., 2014; Wang, Gao, Yin, & Yu, 2012; Zhivov et al., 2013) . Upon corneal epithelial wounding, severed subbasal nerves regenerate significantly slower in diabetic than in nondiabetic animals Wang et al., 2012) . The sub-basal nerve alterations in diabetic mice are accompanied by abnormalities of dendritic cells that may serve neurotrophic functions Leppin et al., 2014) . Several studies have documented corneal neuropathy early in diabetes, before the development of DR (Papanas & Ziegler, 2013; Petropoulos et al., 2015; Szalai et al., 2016; Zhivov et al., 2013) . Moreover, in rat models, corneal nerve damage occurred not only in animals with NIDDM but also in those that were obese but non-diabetic, suggesting that corneal neuropathy may develop even before the onset of hyperglycemia (Davidson et al., 2014) and calling for therapeutic interventions in pre-diabetes. Along with keratopathy, diabetic neuropathy is considered a hallmark of diabetes in the cornea and an important factor for noninvasive diagnostics (Cruzat, Qazi, & Hamrah, 2017; Saini & Mittal, 1996a; Saito et al., 2003; Tavakoli et al., 2007) .
Stromal changes
To date, there are only a few studies of the corneal stroma in diabetics. In patients with NIDDM corneal stroma acquires abnormal collagen fibril bundles of variable thickness (Rehany, Ishii, Lahav, & Rumelt, 2000b) . In monkeys with induced IDDM similar stromal bundles were found (Zou, Wang, Huang, & Zhang, 2012) . Importantly, the diabetic corneal stroma accumulates AGEs, which may lead to collagen crosslinking and could contribute to increased central corneal thickness (Sady, Khosrof, & Nagaraj, 1995) . This accumulation may also underlie changes in type IV collagen expression, impaired cell adhesion, and increased keratocyte apoptosis observed in mice with NIDDM and in rats with IDDM (Kim et al., 2011; Watanabe, Katakami, Miyata, & Negi, 2002) . In diabetic rats, stromal edema was also reported (Gül, Emre, Es ßrefoglu, & Vard, 2008) . The thickness and tortuosity of stromal nerves appears to be increased in diabetic patients (Mocan et al., 2006) . Two matrix metalloproteinases (MMP), MMP-3 and MMP-10 were found to be upregulated in the stroma of human diabetic but not keratoconic corneas (Saghizadeh, Brown et al., 2001) , which may contribute to altered stromal maintenance and remodeling.
Corneal endothelial abnormalities
Several studies have evaluated the morphology, number and function of corneal endothelium in diabetic patients. Endothelial cell morphology is reportedly changed in diabetics with increased pleomorphism and variability of the cell area (El-Agamy & Alsubaie, 2017; Larsson, Bourne, Pach, & Brubaker, 1996; Matsuda, Ohguro, Ishimoto, & Fukuda, 1990; Módis et al., 2010; Roszkowska, Tringali, Colosi, Squeri, & Ferreri, 1999; Shenoy, Khandekar, Bialasiewicz, & Al Muniri, 2009; Weston, Bourne, Polse, & Hodge, 1995) . Some data indicate no change in cell density (Larsson et al., 1996; Matsuda et al., 1990) , whereas more recent results show decreased in vivo endothelial cell counts in corneas of patients with IDDM and NIDDM (El-Agamy & Alsubaie, 2017; Inoue, Kato, Inoue, Amano, & Oshika, 2002; Liaboe et al., 2017; Roszkowska et al., 1999; Shenoy et al., 2009) . A similar controversy surrounds endothelial function: some studies found that it was decreased compared to non-diabetic corneas in terms of deswelling (Saini & Mittal, 1996b) , but others failed to confirm this finding (Larsson et al., 1996; Weston et al., 1995) . Although most studies did not specifically address the issue of endothelial loss severity or the presence of DR, endothelial diabetic changes seem to be rather minor overall. However, diabetes carries increased risk of endothelial complications following corneal surgery.
Conjunctival involvement
Abnormalities of the conjunctiva are common in diabetic patients (Gunay et al., 2016; Yoon et al., 2004) . Problems specifically related to conjunctiva include microvascular alterations partly similar to the retinal ones, including loss of capillaries, macrovascular dilation, uneven vessel distribution, and low numbers of goblet cells (Cheung, Ramanujam, Greer, Kumagai, & Aoki, 2001; Owen, Newsom, Rudnicka, Ellis, & Woodward, 2005; To, Telander, Lloyd, Chen, & Cheung, 2011; Yoon et al., 2004) . Antiangiogenic ranibizumab was effective in ameliorating conjunctival sensitivity in diabetics (Örnek, Örnek, & Erbahçeci, 2015) . Diabetic conjunctiva with dry eye also shows increased proinflammatory cytokines (Zhang et al., 2016) . Interestingly, conjunctival flora appears to be abnormal in diabetic patients (Bilen et al., 2007; Martins et al., 2004) . These patients have a significantly higher percentage of positive cultures than non-diabetic patients. The pattern of predominant bacterial strains (mostly Staphylococcus) also differs from control subjects with Gram-negative bacteria being more common (Adam et al., 2015; Bilen et al., 2007) . Resistance of these strains to penicillin, streptomycin, and tetracycline increases the risk of postoperative endophthalmitis in diabetic patients because the conjunctiva may not be adequately sterilized before surgery. Vancomycin should be used in these cases because of lack of resistance to its action (Bilen et al., 2007) .
Tear film changes
Tear film plays a significant role in corneal health and immune protection. It is mainly produced by the lacrimal gland that shows signs of inflammation, hyperglycemia-related oxidative stress, and accumulates AGEs in human and animal diabetes (Alves, Carvalheira, Módulo, & Rocha, 2008; Módulo et al., 2009) . As a result, tear secretion in diabetics is often significantly lower than normal, and dry eye incidence increases (Beckman, 2014; Cousen et al., 2007; Dogru, Katakami, & Inoue, 2001; Inoue et al., 2001; Manaviat et al., 2008; Yoon et al., 2004) . Osmolarity of diabetic tears also increases (Beckman, 2014) . In diabetic patients, decreased stability of tear film correlates with neuropathy, poor glucose control, and reduced density of conjunctival goblet cells that secrete tear mucins (Dogru et al., 2001; Yoon et al., 2004) . The severity of keratoconjunctivitis sicca was found to correlate with the severity of DR (Lv et al., 2014; Manaviat et al., 2008; Nepp, Abela, Derbolav, & Wedrich, 2000) . Overall, diabetic tear film abnormalities and dry eye are serious clinical problems and may also contribute to diabetic keratopathy (Liu et al., 2015) .
Biomechanical abnormalities
Corneal diabetic alterations include increased central thickness, altered BM composition, abnormal collagen structure in the stroma and accumulation of AGEs that may cause collagen crosslinking (Ljubimov et al., 1996; El-Agamy & Alsubaie, 2017; Rehany et al., 2000b; Zou et al., 2012) . Therefore, corneal biomechanics may be also altered in diabetics. This issue has been explored in several human studies measuring corneal resistance factor (CRF; related to the elasticity and overall resistance of the cornea), and corneal hysteresis (CH; related to viscoelastic properties and indicating biomechanical integrity) using ocular response analyzer. These studies also established an increase in corneal thickness associated with diabetes (Kotecha et al., 2010; Scheler, Spoeri, & Boehm, 2012) . The reported changes are inconsistent. One study found a decrease in CH (lower viscosity) and no change in CRF (Sahin, Bayer, Ozge, & Mumcuoglu, 2009 ), but two other studies reported an increase in both parameters (Kotecha et al., 2010; Scheler et al., 2012) . The discrepancy may arise from the fact that the first study did not measure the glycation levels (as glycated hemoglobin Hb1Ac). In contrast, two other studies showed a significant correlation between Hb1Ac values and biomechanical parameters. The data suggest that biomechanical properties of the cornea are altered more with poorer diabetes control manifested by high Hb1Ac. Although corneal biomechanical changes in diabetes seem to correlate with altered metabolism, their contribution to pathophysiology remains to be established. Overall, it appears that diabetic corneas become progressively more viscoelastic and more resistant to pressure, possibly due to increasing protein glycation and crosslinking. This view is consistent with protective effect of NIDDM on keratoconus, a thinning corneal degeneration, characterized by corneal protrusion and low biomechanical parameters (Seiler, Huhle, Spoeri, & Kunath, 2000) .
Surgical problems
Structural and functional abnormalities in diabetic corneas contribute to an increased risk of surgical complications. Even with improved surgical techniques individuals with diabetes account for 80% of cases of corneal complications after cataract and refractive surgery, vitrectomy for non-clearing vitreous hemorrhage, and PRP (Bikbova et al., 2012; Chen et al., 2009; Chiambo et al., 2004; Chung, Tolentino, Cajita, Acosta, & Refojo, 1988; Dogru et al., 2004; Foulks, Thoft, Perry, & Tolentino, 1979; Hiraoka, Amano, Oshika, Kato, & Hori, 2001; Vieira-Potter et al., 2016; Wylegała et al., 2006) . In some patients, diabetic keratopathy may develop following ocular surgery (Chen et al., 2009; Sakamoto, Sasaki, & Kitagawa, 2004) . Upon vitrectomy and PRP these problems arise as a consequence of epithelial debridement usually performed to improve intraoperative visualization (Chen et al., 2009; Schulze, Sekundo, & Kroll, 2006) . During debridement subbasal nerve endings are severed and regrow slower than normal. Combined insult on epithelial cells and subbasal nerves underlies slow wound healing and temporary reduction (up to six months) in corneal sensation postoperatively (Chen et al., 2009; Mahgoub & Macky, 2014) . For this reason, additional treatment, e.g., autologous serum has been used in these patients to accelerate the wound healing process (Schulze et al., 2006) . Cataract surgery may bring about an increase in corneal thickness and in endothelial cell loss compared to non-diabetic patients (Dhasmana, Singh, & Nagpal, 2014; Hugod et al., 2011; Langwiń ska-Wośko, ChociszewskaNitka, Zieliń ska, & Hapunik, 2004; Lee, Lee, Choi, Oum, & Cho, 2005; Morikubo, Takamura, Kubo, Tsuzuki, & Akagi, 2004; Yang et al., 2011) . Corneal edema after phacoemulsification during cataract surgery is also more persistent in diabetics (Tsaousis, Panagiotou, Kostopoulou, Vlatsios, & Stampouli, 2015) , who are also at higher risk of graft failure in Descemet's membrane keratoplasty (Greiner et al., 2014) .
Refractive surgery including photorefractive keratotomy and LASIK is more risky in diabetics because of recurrent erosions and persistent epithelial defects, epithelial downgrowth, keratitis, poor wound healing, and increased possibility of infections (Costin, 2001 : Fraunfelder & Rich, 2002 Jabbur, Chicani, Kuo, & O'Brien, 2004) . LASIK in some cases can aggravate DR (Ghanbari & Ahmadieh, 2003) . This procedure could be recommended only to patients with well-controlled diabetes and without diagnosed DR (Cobo-Soriano, Beltrán, & Baviera, 2006; Halkiadakis, Belfair, & Gimbel, 2005) . However, some ophthalmologists continue to caution against performing refractive surgery in all diabetic patients (Mohammadpour, 2007) .
Molecular alterations and disease markers of diabetes in the cornea
Despite clinical relevance, there is still no comprehensive picture of the molecular mechanisms of diabetic corneal disease. Because of its clear involvement, the corneal epithelium has been the main focus of such studies. In this section, major findings will be described, mostly related to the epithelial wound healing and stem cells, and various factors that may play a role in the development of diabetic keratopathy. The list of components altered in human and animal diabetic corneas is provided in Table 2 . In this section the data on IDDM and NIDDM are discussed together, as no significant differences in corneal molecular alterations between two types are currently known.
Cell adhesion and basement membrane
It has been long recognized that diabetic corneal changes involved abnormal interactions of corneal epithelium with altered epithelial basement membrane (BM). These abnormalities include increased BM fragility, decreased number of hemidesmosomes, altered epithelial adhesion, and delayed BM reassembly after wounding (Azar, Spurr-Michaud, Tisdale, & Gipson, 1989; Hatchell et al., 1983; Tabatabay, Bumbacher, Baumgartner, & Leuenberger, 1988; Azar, Spurr-Michaud, Tisdale, & Gipson, 1992; Gül et al., 2008; Sato, Nakamura, Chikama, & Nishida, 1999) . In human diabetic epithelial BM distinct reduction in immunostaining was further found for its major components, chains of laminin-511/laminin-10 (a5b1c1), nidogen-1/entactin, and a 3 b 1 laminin-binding integrin, which was more pronounced in the corneas of patients with DR (Fujita et al., 2003; Ljubimov et al., 1998) . Laminin c3 chain and fibronectin were also decreased in the diabetic limbal epithelial BM (Saghizadeh et al., 2011) . These data are consistent with reduced corneal epithelial cell adhesion in high glucose condition (Lu, Ebihara, Miyazaki, & Murakami, 2006) . Diabetic BM fragility leads to easy removal of cells with BM by manual debridement, which does not happen in normal corneas. For this reason, wounding of diabetic corneal epithelium should be done by chemical cell removal, e.g., with n-heptanol (Hatchell, Ubels, Stekiel, & Hatchell, 1985; Kabosova et al., 2003) . Our subsequent studies found no changes in gene expression for BM components and a 3 b 1 integrin. At the same time, increased expression and activity of MMP-10 and cathepsin F were observed in diabetic corneas, suggesting that BM and integrin changes were possibly due to protein degradation (Saghizadeh, Brown et al., 2001; Saghizadeh et al., 2005) . The degradation hypothesis was fully supported by experiments on boosting or silencing the expression of these proteinases by adenovirus (AV)-delivered full-length constructs or shRNA, respectively. Increasing MMP-10 and cathepsin F expression in normal corneas led to the discontinuity of immunostaining for chains of laminin-511 and laminin-332, nidogen-1, nidogen-2, and a 3 b 1 integrin (Saghizadeh, Kramerov, Yaghoobzadeh et al., 2010) , whereas proteinase silencing resulted in the normalization of BM and integrin patterns Saghizadeh, Dib, Brunken, & Ljubimov, 2014; Kramerov, Saghizadeh, & Ljubimov, 2016; . The available evidence suggests that epithelial BM and cell adhesion abnormalities may result from degradative processes in the diabetic cornea and may negatively impact epithelial wound healing.
The second corneal BM, the Descemet's membrane, has been much less studied in diabetic conditions. Data obtained in rats with either IDDM or NIDDM show that diabetic Descemet's membrane contains unusual wide-spaced collagen bundles and more than normal long-spacing collagen fibrils (Akimoto, Sawada, Ohara-Imaizumi, Nagamatsu, & Kawakami, 2008; Rehany, Ishii, Lahav, & Rumelt, 2000a) . These data have been corroborated in corneas from patients with NIDDM (Rehany et al., 2000b) . The authors suggest that collagen bundle appearance may be a result of excessive collagen glycation, although metabolic abnormalities of diabetic endothelial cells cannot be ruled out.
Proteinases
Proteolytic enzymes (MMPs, plasminogen activators, cathepsins, etc.) play a major role in embryonic development, blood coagulation, wound healing and tissue remodeling. As diabetic corneas have slow and incomplete epithelial wound healing, and BM fragility and fragmentation, it is possible that proteinases are involved in these alterations. In fact, corneal epithelial cells in high glucose and rat diabetic corneal epithelium showed enhanced MMP activity during wound healing (Takahashi et al., 2000) . Using gene microarrays, immunostaining, and zymography, our group has shown that ex vivo human diabetic corneas upregulated the expression of MMP-10 in the epithelium and keratocytes, MMP-3 in the keratocytes, and cathepsin F in the epithelium (Saghizadeh, Brown et al., 2001; Saghizadeh et al., 2005) . These changes were not seen in keratoconus or bullous keratopathy corneas, suggesting specific changes induced by diabetes. Some other MMPs (1, 2, 7, 11, 13) were downregulated, but several cathepsins, and plasminogen activators remained unchanged according to gene microarray analysis (Saghizadeh et al., 2005) . Specific proteinase upregulation in diabetic corneas has functional implications, as shRNA-mediated downregulation of MMP-10 and cathepsin F in organ-cultured diabetic corneas accelerated wound healing and restored altered epithelial BM and integrin patterns (Kramerov, Saghizadeh et al., 2016; Saghizadeh et al., 2013; . Mouse diabetic corneas were recently found to have abnormal regulation of Serpine1/plasminogen activator inhibitor-1 in MiR-146a Human Increased in the epithelium Funari et al., 2013 MiR-204-5p Mouse Increased in the epithelium Gao et al., 2015 epithelial wound healing. Serpine1 levels were lower than normal during healing, and its addition accelerated the healing process (Sun, Mi, Gao, & Yu, 2015) . Thus, specific proteinases may be promising targets for therapy aiming at preventing or alleviating symptoms of diabetic corneal epitheliopathy.
Growth factors and signaling molecules
Growth factors and cytokines are powerful regulators of cell behavior and tissue remodeling including wound healing. Specific growth factors have altered levels in diabetic tissues, and new treatments aimed at blocking their abnormal expression are being successfully tested in clinical trials (Aiello, Cahill, & Cavallerano, 2004; Aiello & Hata, 1999; Amoaku, Saker, & Stewart, 2015; Caldwell et al., 2003) . Since growth factors and cytokines affect corneal cell behavior and wound healing (Imanishi et al., 2000; Klenkler & Sheardown, 2004; Wilson, Liu, & Mohan, 1999) , they may play a role in diabetic keratopathy. Altered expression of growth factors/cytokines may contribute to BM changes, decreased cell adhesion, epithelial fragility, abnormal wound healing, and subbasal nerve loss typical for diabetic corneas. Some better-studied growth factor systems with relevance to diabetic corneal disease are discussed below.
Opioid growth factor system
Opioid growth factor (OGF, or [Met 5 ]-enkephalin) and its f receptor (OGFR) is an important system mediating corneal homeostasis, and acting as a negative regulator of epithelial proliferation and wound healing (Sassani, Mc Laughlin, & Zagon, 2016) . Elevated levels of OGF are found in the plasma of diabetic patients and in the obese diabetic (db/db) mice (McLaughlin, Sassani, Klocek, & Zagon, 2010) . OGF-OGFR system is expressed in the corneal cells, and its systemic or topical blockade by opioid antagonists enhances corneal epithelial wound healing in rats and rabbits with IDDM. This effect was also reported for non-diabetic animals and organ cultures of normal human corneas (McLaughlin et al., 2010) . Wound healing acceleration was accompanied by increased cell proliferation, which is thought to be the main mechanism behind the antagonist effect.
3.4.1. Insulin-like growth factor-1 (IGF-1) IGF-1 is important for cell growth and metabolism. In corneal epithelial cells it acts through insulin receptor, and IGF receptors. IGF-1 and its receptors are found in human corneal keratocytes and epithelial cells (Li & Tseng, 1995) , and mediate cell migration, proliferation, and survival (Lee et al., 2006; Yanai, Yamada, Inui, & Nishida, 2006) . In ex vivo human diabetic corneas IGF-1 expression is significantly elevated, especially in the epithelium (Saghizadeh, Chwa et al., 2001) . In corneas of diabetic rats IGF-1 synergizes with a neuropeptide substance P in accelerating epithelial wound healing (Nakamura et al., 2003) . IGF-1 can bind to several proteins (IGFBPs) that modulate the bioavailability of extracellular IGF-1, preventing its activation of the IGF-1R and function (Wu, Buckner, Zhu, Cavanagh, & Robertson, 2012) . IGFBP3 is elevated in diabetic tears and immortalized corneal epithelial cells in hyperglycemic conditions. Moreover, in vitro phosphorylation of IGF-1R was blocked in the presence of IGFBP3 and IGF-1 when given to corneal cells at a high diabetic but not at a low normal ratio (Wu et al., 2012 ). It appears that elevated levels of IGF-1 alone in diabetic corneas may not be beneficial for corneal wound healing and epithelial maintenance due to the interference by elevated tear IGFBP3. Another related key metabolic regulator present in tears is insulin but its changes in the diabetic corneas have not been explored.
Epidermal growth factor (EGF)
EGF signals through its receptor (EGFR1/ErbB1, or EGFR) to activate intracellular pathways comprising downstream protein kinase effectors, phosphatidylinositol-3-kinase (PI3K) -Akt kinase axis, and extracellular regulated kinase (ERK) (Funari et al., 2013; Winkler, Dib, Ljubimov, & Saghizadeh, 2014; Xu & Yu, 2011; Xu et al., 2009; Zhang & Akhtar, 1997 ). This pathway is critical for cell migration and proliferation, and is a major mediator of corneal epithelial wound healing Nakamura, Sotozono, & Kinoshita, 2001; Zieske, Takahashi, Hutcheon, & Dalbone, 2000) . In corneas of rats with IDDM phosphorylation of EGFR and its signaling intermediates Akt and ERK was diminished, as well as downstream apoptotic BAD signaling pathways. These abnormalities were associated with a significant delay in corneal epithelial wound healing compared to nondiabetic animals (Xu & Yu, 2011) . Similar changes were observed in corneal epithelial cells and organ-cultured porcine and human corneas in high glucose (Xu et al., 2009) . The relationship of EGFR signaling with diabetic corneal wound healing was further tested by manipulating levels of diabetes-increased proteinases in normal and diabetic organ-cultured human corneas. Overexpression of MMP-10 and cathepsin F in normal corneas decreased phospho-EGFR and phospho-Akt expression, whereas phospho-ERK and phospho-p38 remained unchanged. This was accompanied by slower epithelial wound healing (Saghizadeh, Kramerov, Yaghoobzadeh et al., 2010) . Conversely, silencing of these proteinases in diabetic corneas increased phospho-EGFR and phospho-Akt expression and accelerated wound healing Saghizadeh et al., 2014) . Overall, EGFR signaling is downregulated in the diabetic corneas, which may negatively impact epithelial wound healing.
Hepatocyte growth factor (HGF)
HGF in the cornea is mostly produced by the epithelial cells, whereas its receptor, c-met proto-oncogene is made by stromal cells, but also by the epithelium. HGF and c-met mRNAs are found in all three major cell types of the human cornea (Wilson, Walker, Chwang, & He, 1993) , suggesting the existence of autocrine loops in corneal endothelium and epithelium. HGF is involved in cell proliferation, migration, and apoptosis (Kakazu, Chandrasekher, & Bazan 2004; Saghizadeh, Kramerov, Yu, Castro, & Ljubimov, 2010; Saghizadeh et al., 2011; Wilson et al., 1993) . During corneal epithelial wound healing HGF is upregulated in both keratocytes and epithelial cells (Kakazu, Sharma, & Bazan, 2008; Li et al., 1996; Saghizadeh, Kramerov, Yu et al., 2010) . Using gene microarray analysis validated by immunostaining, RT-PCR, and functional assays, we have documented upregulation of HGF in donor human diabetic corneas. At the same time, these corneas showed downregulation of c-met receptor (Saghizadeh et al., 2005) . Upregulation of c-met in organ-cultured human diabetic corneas led to marked normalization of diabetic marker patterns and wound healing time. Analysis of signaling intermediates identified p38 mitogen-activated protein kinase as the major downstream effector of the HGF-c-met pathway (Saghizadeh, Kramerov, Yu et al., 2010; Sharma, He, & Bazan, 2003) . These data support the hypothesis that the alterations of HGF-c-met system contribute to abnormalities observed in diabetic corneas (Saghizadeh et al., 2005; Saghizadeh, Kramerov, Yu et al., 2010; Saghizadeh et al., 2011; Saghizadeh et al., 2014; Kramerov, Saghizadeh et al., 2016) .
Thymosin b 4
Tb 4 is a member of the b-thymosin family of conserved 5 kDa peptides. They interact with G-actin and are actin-sequestering proteins (Dedova, Nikolaeva, Safer, De La Cruz, & dos Remedios, 2006) . Tb 4 has many other biological activities, and is one of the mediators of cell migration, angiogenesis, inflammation, and tissue regeneration. Tb 4 promotes corneal re-epithelialization during healing, and inhibits apoptosis both in vitro and in vivo. One of the main mechanisms of Tb 4 action is thought to be blocking of tumor necrosis factor-a (TNF-a) induced inflammation and related NF-jB activation (Sosne, Qiu, Kurpakus-Wheater, & Matthew, 2010) . Tb 4 also upregulates epithelial BM component laminin-332 (laminin-5), which mediates epithelial migration, as well as diabetes-downregulated MMP-1 (Sosne et al., 2004; Sosne, Qiu, & Kurpakus-Wheater, 2007; Sosne et al., 2010) . In the cornea, Tb 4 is mostly found in the epithelial cells. Gene microarray analysis and immunohistochemistry revealed significant decrease of Tb 4 in human diabetic corneas (Saghizadeh et al., 2005) , which may be related to slow wound closure by epithelial cells and increased cell death. Tb 4 thus appears to be a promising target for therapy aimed at restoring normal wound healing and reducing apoptosis in the diabetic cornea.
Other factors altered in diabetic corneas
Several more factors have been identified as altered in diabetic corneas and appear to contribute to diabetic complications.
Diabetic corneas have significant epithelial stem cell abnormalities manifested by decreased expression of a number of putative stem cell markers (Saghizadeh et al., 2011; Ueno et al., 2014) . These alterations may contribute to slow wound healing, as therapeutic restoration of the expression patterns was accompanied by normalized wound healing in organ cultured diabetic corneas and stem cell-enriched limbal epithelial cultures (Kramerov, Saghizadeh et al., 2016; Saghizadeh et al., 2011; Saghizadeh et al., 2013; Saghizadeh et al., 2014) .
Recent studies have revealed altered purinergic signaling in diabetic corneal wound healing. Activation of this signaling is thought to be one of the first events in the wound healing process . In diabetic corneas of humans, rats and mice ATP-activated P2X7 receptor is increased (Mankus, Rich, Minns, & Trinkaus-Randall, 2011 ). This could contribute to slow epithelial wound healing in these tissues (Minns & TrinkausRandall, 2016) .
Genome-wide transcriptional analysis of healing corneal epithelium in rats with IDDM and NIDDM, and mice with IDDM recently revealed downregulation of transforming growth factor (TGF)-b3, an anti-fibrotic TGF-b isoform. The administration of TGF-b3 accelerated wound closure in diabetic animals via SMAD and PI3K-Akt pathways and upregulation of Serpine1 (Bettahi et al., 2014) , suggesting its possible translational use in diabetic patients.
Corneal epithelium of diabetic patients, and high glucoseexposed cultured epithelial cells have increased immunoreactivity for ephrin-A1, a member of cell-cell signaling family and a negative mediator of cell migration. It is a ligand for tyrosine kinase EphA2 receptor, mutations of which are associated with cataract formation (Kaplan et al., 2012) . In cultured corneal epithelial cells, ephrin-A1 activation of EphA2 restricted cell migration while suppressing activation of ERK1/2 and Akt kinases (Kaplan et al., 2012) . The data suggest that ephrin-A1/EphA2 as an inhibitor of cell migration may be a mediator of slow diabetic epithelial wound healing in the cornea.
The advent of genome-wide transcriptome sequencing may soon bring about new markers of diabetic corneas that would facilitate the development of new therapeutics against diabetic corneal disease.
Advanced glycation end products (AGEs)
Hyperglycemia in diabetics causes non-enzymatic glycosylation of proteins leading to the formation of AGEs that accumulate in diabetic tissues (Madonna, Balistreri, Geng, & De Caterina, 2017; Zou et al., 2012) . AGEs interact with their receptors (RAGEs) triggering intracellular signaling including NF-jB activation and formation of reactive oxygen species (ROS) (Kim et al., 2011; Shi, Chen, Yu, & Wu, 2013; Shi, Yu, Yang, & Wu, 2013) . Their accumulation in the diabetic corneal BMs and stroma may be responsible for clinically observed increased autofluorescence (Calvo-Maroto et al., 2016; Kaji et al., 2000; McDermott, Xiao, Kern, & Murphy, 2003) . In cultured corneal telomerase-immortalized epithelial cells AGEs cause delayed wound healing and increased cell apoptosis in a ROS-and RAGE-dependent manner (Shi, Chen et al., 2013; Shi, Yu et al., 2013) . This was accompanied by activation of NADPH oxidase generating ROS, as well as JNK and p38 kinase pathways. AGEs may cause stromal collagen crosslinking altering corneal biomechanics (Sady et al., 1995) .
AGEs may affect epithelial and keratocyte attachment to the diabetic corneal extracellular matrix. Corneal epithelial cells poorly attach to glycated type I collagen, fibronectin, and laminin (McDermott et al., 2003) . Glycated laminin and fibronectin mimicking diabetic Descemet's membrane only poorly support corneal endothelial cell adhesion (Kaji et al., 2000; Kaji et al., 2001 ). Thus, increased corneal oxidative stress through RAGE signaling and direct adhesive protein modifications by AGEs may exacerbate diabetic abnormalities.
Polyol pathway
The polyol pathway is known to be activated in diabetes, whereby excess glucose is converted to sorbitol by aldose reductases, e.g., AKR1B1 and AKR1B10 (Huang et al., 2010) . Accumulation of sorbitol pathway products is important for diabetic cataract formation (Huang et al., 2010) , but its consequences are less studied in the cornea. Inhibitor studies in galactosemic rats showed normalization of delayed epithelial wound healing by aldose reductase inhibitor treatment (Datiles, Kador, Fukui, Hu, & Kinoshita, 1983) , which may have translational significance.
MicroRNA
MicroRNAs are powerful biological regulators with mostly negative effects on gene expression. These effects are complex due to the action of each miRNA on more than one cellular target. Using miRNA arrays, Saghizadeh et al. have identified a number of miRNA differentially expressed in diabetic human corneas (Funari et al., 2013) . Two miRNAs, h-miR-146a and h-miR-424 were upregulated in diabetic corneas and retarded corneal epithelial wound healing both in cultured cells and organ-cultured corneas, whereas their specific inhibitors accelerated healing (Funari et al., 2013; Winkler et al., 2014) . MiR-146a inhibition was accompanied by increased expression of phospho-EGFR, phospho-p38, and a diabetic marker, integrin a 3 b 1 (Winkler et al., 2014) . Western analysis of cells treated either by mir-146a or its inhibitor identified EGFR as a target for this miRNA, compatible with its effects on wound healing (Funari et al., 2013) . Recently, miR-204-5p increase in diabetic corneas was observed in the Akita mouse model of IDDM (Gao, Wang, Zhao, Chen, & Xie, 2015) . In the cornea, this miRNA suppresses it target, silent mating type information regulation 2 homolog 1 (SIRT1). In limbal epithelial cell line grown in high glucose miR-204-5p was increased and SIRT1 inhibition occurred. Downregulation of miR-204-5p by a specific inhibitor restored cell growth. In Akita mice, subconjunctival injections of miR-204-5p inhibitor promoted wound healing with upregulation of SIRT1 and cyclin D1 . Although studies of miRNA changes in diabetic corneas have just begun, they have already identified possible candidates responsible for corneal abnormalities and amenable for therapeutic interventions.
In vitro systems for studies of diabetes in the cornea
Corneal cell cultures in normal (5 mM) and high (25-30 mM) glucose with mannitol control for osmolarity have been widely used to mimic diabetic alterations, in order to examine molecular mechanisms of wound healing and test certain drug candidates. Most studies dealt with epithelial cells including SV40 T antigentransformed (now mostly abandoned), and telomeraseimmortalized cells that are closer to the corneal epithelium Lu et al., 2006; Xu et al., 2009; Yang et al., 2014; Yin & Yu 2010) . It should be borne in mind that immortalized cells are closer to the epithelial progenitors than to differentiated epithelial cells of the central corneas, which may be a drawback. Stem cell-enriched human primary limbal epithelial cultures have also been used to study wound healing. These cultures preserve slower healing and alterations in marker patterns similar to the in vivo corneas (Kramerov, Saghizadeh, Maguen, Rabinowitz, & Ljubimov, 2015) , possibly due to stable epigenetic changes typical for tissues of long-term diabetics (Chen et al., 2016; Kowluru, Kowluru, Mishra, & Kumar, 2015) . Limbal cultures may be more suitable for diabetes research than immortalized cell lines derived from normal cells and put in a transient high glucose environment. Stromal diabetic cells have not been studied in detail yet. Recently, a culture system using diabetic donor corneal stromal cells for making 3D diabetic stromal models was introduced and revealed significant alterations in these cells (Priyadarsini, Sarker-Nag, Rowsey, Ma, Karamichos, 2016) .
A better model is represented by whole corneal organ culture that even allows for a successful corneal transplantation (Devasahayam et al., 2016) . Using one of these models where the corneas are kept at the air-liquid interface and maintained at normal corneal temperature of around 35°C, we have successfully shown that organ-cultured corneas from DM and DR patients preserved the delayed wound healing and abnormal BM structure, proteinase and growth factor patterns that are seen in intact corneas from such patients (Kabosova et al., 2003; Kramerov, Saghizadeh et al., 2016; . Diabetic changes persist in organ cultures for more than a month as a maximum culture period, possibly due to the epigenetic phenomenon of diabetic memory (Chen et al., 2016; Kowluru et al., 2015) . These cultures allowed us to work out successful gene therapy alleviating some traits of diabetic keratopathy such as slow wound healing (Kramerov, Saghizadeh et al., 2016; . Corneal organ cultures are thus suitable not only for studying diabetes-related changes (with a known drawback of lack of innervation and blood flow), but also for testing possible drugs aimed at ameliorating signs of diabetic corneal disease (Kramerov, Saghizadeh et al., 2016) .
Animal models
Models of IDDM and NIDDM have been established in the rabbit, mouse, rat, guinea pig, cat, dog, pig, and monkey. All models mimic fairly early signs of human diabetic ocular disease. However, diabetic animals only develop background DR but do not show signs of PDR, and have no macula (except for non-human primates) to develop macular edema seen in many diabetic patients (Stitt et al., 2016) . At the same time, some corneal symptoms in these models are similar to humans, which allows studying mechanisms of slow epithelial wound healing and reduced innervation (Byun, Kang, Yoo, & Joo, 2015; Chikama et al., 2007; Sassani et al., 2016; Wang et al., 2012; Yin et al., 2011) . However, some traits of diabetes in the cornea of animals differ from human disease. Delayed epithelial wound healing was seen in rats but not rabbits (Hatchell et al., 1983; Nakamura et al., 2003) . However, diabetic rabbits as humans have degradative BM changes as in human corneas, but diabetic rats and mice show increased BM staining for laminin (Hatchell et al., 1983; Nakamura et al., 2003; Watanabe et al., 2002) . A mouse IGF-1 transgenic model develops retinal signs of diabetes but no corneal changes (Ruberte et al., 2004) . Overall, animal models of diabetic keratopathy should be well characterized for a particular diabetic symptom or a group of symptoms to study, and the data compared to the human situation. A necessity for comparative studies of both animal and human material has been emphasized (Eisma, Dulle, & Fort, 2015) .
Treatment possibilities
Diabetic keratopathy and diabetic neuropathy treatment remains largely symptomatic (Abdelkader et al., 2011; Cavallerano, 1992) . Several treatment modalities have been developed and tested in recent years, but many of them are currently at the experimental stage. The most promising approaches are discussed below and summarized in Table 3 . It should be noted that the emerging drugs with the exception of naltrexone have not been tested in both types of diabetes, which may be needed in the future if their potential molecular differences are identified.
Insulin
Insulin is an obvious drug to use against diabetes and its complications (both IDDM and severe cases of NIDDM). Local insulin implants can accelerate corneal wound healing in rats with IDDM (Klocek, Sassani, McLaughlin, & Zagon, 2007) . In IDDM mice, insulin eye drops were able to prevent the loss of subbasal corneal nerves . Recently, insulin was shown to restore diabetes-altered circadian rhythm in the corneal epithelium, which may be a mechanism of its beneficial action (Song et al., 2016) . In a clinical setting, insulin eye drops were successfully used in 14 diabetic patients who had corneal epithelial debridement before vitreoretinal surgeries. With this treatment, corneas re-epithelialized significantly faster than without it (Bastion & Ling, 2013) . These data suggest that insulin treatment may be used to treat corneal defects in diabetics. IGF-1 that may utilize insulin receptor for signaling has been tested for the prevention of diabetic keratopathy in NIDDM mice (db/db). Retrobulbar injections of recombinant IGF-1 were able to prevent decreased expression of epithelial stem cell markers in diabetic mice, as well as to increase subbasal nerve density (Ueno et al., 2014) .
As a note of caution, the efficacy of insulin or IGF-1 treatment may depend on whether the epigenetic diabetic changes are mild or severe. It should also be noted, that in normal corneas insulin does not accelerate wound healing (Abdelkader et al., 2011) . Moreover, in diabetic organ-cultured corneas wound healing is still compromised compared to normal corneas despite the presence of high insulin concentration in the medium (Kabosova et al., 2003) . Finally, DR may initially worsen after insulin treatment. This may be a consequence of upregulation of IGF-1 that activates the production of vascular endothelial growth factor and exacerbates retinopathy (Smith et al., 1999) . More data including biodistribution and examination of retinal effects are thus needed before insulin or IGF-1 local therapy can be recommended as a treatment for diabetic keratopathy.
Naltrexone
Naltrexone is an opioid antagonist and an inhibitor of OGF-OGFR interaction (see 3.3.1). It is safe and approved for clinical treatment of alcohol and opioid dependence. It has been convincingly shown by Zagon's group to normalize corneal epithelial wound healing, tear secretion, and corneal surface sensitivity in diabetic animals (McLaughlin et al., 2010; Sassani et al., 2016; Zagon, Sassani, Immonen, & McLaughlin, 2014) . This was established in several animal species with both IDDM and NIDDM . In contrast to many wound healing promoting agents that increase epithelial cell motility, naltrexone apparently lifts a restriction on cell proliferation imposed by OGF (McLaughlin et al., 2010) . The effects of naltrexone on corneal nerves could be mediated by mechanisms other than OGFR silencing (Hota, Srinivasan, Dutta, Bhansali, & Chakrabarti, 2016) . The availability of naltrexone eye drops makes it possible to introduce it to clinical practice for diabetic keratopathy in the near future (Liang, Sassani, McLaughlin, & Zagon, 2016) .
Aldose reductase inhibitors
Studies in galactose-fed rats have shown that they develop corneal abnormalities similar to those found in diabetic animals. Treatment with aldose reductase inhibitor (ARI) ranirestat ameliorated corneal wound healing, and normalized the expression of previously described diabetic markers (Saghizadeh, Brown et al., 2001 ) MMP-10 and integrin a 3 (Takamura et al., 2013) . Another ARI, CT-112, reportedly reversed abnormal epithelial morphology and reduced corneal sensitivity in some diabetic patients (Hosotani, Ohashi, Yamada, & Tsubota, 1995) . However, a randomized placebo-controlled clinical trial with topical CT-112 did not find differences in corneal sensitivity between placebo and ARI groups, although improvement of corneal barrier function in ARItreated group was observed both at four and eight weeks of treatment (Nakahara et al., 1995) . Overall, it is still unclear whether ARI should be clinically used for diabetic keratopathy treatment.
Other pharmacological agents
Tb 4 as a wound healing promoting and anti-inflammatory agent was tested in diabetic patients with Tb 4 neurotrophic keratopathy in a small clinical trial (Dunn et al., 2010) . Treatment with Tb 4 eye drops resulted in a clinically significant reduction of non-healing epithelial defects in all four patients without noticeable side effects. Tb 4 thus appears to be a promising agent to treat diabetic keratopathy (Sosne, Rimmer, Kleinman, & Ousler, 2016) .
Autologous serum increases corneal wound healing in patients with long-term diabetes (Schulze et al., 2006 ), but it is unclear which serum components contribute to the effect. It is thought that adhesive (fibronectin), mitogenic (EGF), and motogenic (TGF-b and EGF) factors may be responsible (Pflugfelder, 2006) .
Antidiabetic agents nateglinide and glibenclamide were shown to suppress Descemet's membrane changes in NIDDM GotoKakizaki rats (Akimoto et al., 2008) . It remains to be established whether they would normalize other symptoms of diabetic keratopathy. Several treatments have also been recently reported to ameliorate some symptoms of diabetes in the cornea using animal models. These include 1,5-isoquinolinediol [poly(ADP-ribose) polymerase inhibitor] that increased corneal sensitivity and epithelial healing in diabetic rats (Byun et al., 2015) ; ciliary neurotrophic factor (downregulated in the diabetic cornea) that activated corneal epithelial stem cells, increased nerve density, and promoted epithelial healing through the activation of STAT3 in diabetic mice (Zhou et al., 2015) ; topical nerve growth factor that reduced apoptosis and inflammation in corneas of diabetic rats (Park, Kang, Kim, & Tchah, 2016) ; interleukin-1 receptor antagonist that increased epithelial wound healing, sensory reinnervation, and reduced apoptosis in diabetic mouse corneas ; substance P that produced similar effects in diabetic mice and high glucose-treated corneal epithelial cells through neurokinin-1 receptor (Yang et al., 2014) ; curcumin that promoted wound healing and recovery of cor- neal sensation when used in nanomicelles with intranasal delivery; it may work through reduction of reactive oxygen species (Guo et al., 2016) ; and topically delivered mitogenic protein lacritin fused with elastin-like polypeptide-based nanoparticles that enhanced corneal epithelial wound healing in NOD diabetic mice . Although promising, most of these agents need to be studied in more detail including pharmacology and side effects. It is also possible that the best treatment results would be eventually achieved by a combination of several agents (Davidson, Holmes, Coppey, & Yorek, 2015) . Due to superior tissue penetration, nanoformulations may increase the effect.
Gene therapy
Gene therapy has been successfully used for different tissues including the cornea. Viruses are mostly used in these studies because they are very efficient gene delivery vehicles . Despite lasting effects and high efficiency, viruses may induce immune reactions, inflammation, and uncontrolled virus integration into the host genome. New recombinant adenoviruses, adeno-associated viruses, and lentiviruses do not elicit serious immune responses, and transfect non-dividing cells. However, safety concerns remain, including noted toxicity for stem cells. Viral gene therapy has been applied by our group for normalization of organ-cultured human corneas from long-term diabetic donors using AV as delivery vehicle (Kramerov, Saghizadeh et al., 2016) . AV is internalized by the corneal epithelium through caveolae pathway, which can be activated by phosphodiesterase-5 inhibitors (e.g., Viagra) to boost virus uptake (Saghizadeh, Kramerov, Yaghoobzadeh et al., 2010) . Targets for therapy were selected from previous gene microarray and MMP studies and included c-met, MMP-10 and cathepsin F (Saghizadeh, Brown et al., 2001; Saghizadeh et al., 2005) . C-met was downregulated in diabetic corneas and gene therapy with full-length c-met cDNA was aimed at restoring its levels. Proteinases were upregulated in the diabetic corneas, and their expression was silenced by shRNA technology. Increased expression of c-met using AV vector normalized the expression of diabetic BM and integrin markers, accelerated epithelial wound closure, and restored the expression of putative stem cell markers in the limbus (Saghizadeh, Kramerov, Yu et al., 2010; Saghizadeh et al., 2011; Saghizadeh et al., 2014) . The main signaling pathway of c-met action involves p38 (Saghizadeh, Kramerov, Yu et al., 2010) . Similar albeit weaker effects were observed with proteinase silencing, which was accompanied by the activation of the EGFR-Akt pathway Saghizadeh et al., 2014) . The strongest effect was seen with combination therapy using all three AVs. In this case, both p38 and EGFRAkt pathways were activated, which may explain the enhanced effect Saghizadeh et al., 2014) . Interestingly, transduction of stem cell-harboring limbal compartment only was sufficient to normalize various epithelial alterations in the diabetic corneas .
Gene silencing can be also achieved by miRNAs that are important post-transcriptional gene expression regulators. Saghizadeh et al. uncovered a subset of miRNAs that were increased in the diabetic human corneas (Funari et al., 2013) . They further showed that miR-146a increased in the diabetic cornea was able to retard epithelial wound healing by suppressing EGFR, and respective miRNA inhibitor (antagomir) accelerated healing in organcultured diabetic corneas by activating EGFR signaling and restored the expression of some diabetic and stem cell markers (Funari et al., 2013; Winkler et al., 2014) . Despite this success, it should be noted that most miRNAs act on more than one target and are not coordinately changed in different diabetic tissues. Therefore, their use for therapy should be thoroughly validated including the delivery route and biodistribution. Overall, gene therapy appears to be a promising tool for the restoration of diabetic corneal abnormalities and should be further developed for future clinical use.
Stem cells
Human corneal epithelium is rapidly renewed from the limbus, with limbal epithelial stem cells (LESC), or slow-cycling cells, being the source. LESC (1-3.5% of all epithelial cells) also actively participate in epithelial wound healing . Cultured limbal epithelium is enriched in LESC and is often used for transplantation to patients in an autologous or allogeneic manner with considerable success (Holland, 2015) . We have shown previously that LESC in diabetic corneas appear to be dysfunctional because the expression of a number of putative markers is significantly reduced (Saghizadeh et al., 2011) . Specific gene therapy of limbal compartment harboring LESC was able to restore the marker expression levels and accelerate healing of large epithelial wounds . In severe cases of diabetes and with pronounced neuropathy, LESC may become seriously dysfunctional (Ueno et al., 2014; Zhou et al., 2015) , and a transplantation of healthy cells may become an option . Normal LESC may be obtained from donors, especially in cases of bilateral stem cell deficiency. Another source of cells in such severe cases may be hematopoietic stem cells (HSC) obtained from cord blood. In experiments with diabetic rats, injection of human HSC ameliorated corneal epithelial changes (Zickri, Ahmad, Maadawi, Mohamady, & Metwally, 2012) . It remains to be established whether it was a direct or indirect effect.
If a diabetic patient's own LESC are available, they may be propagated in culture (Kramerov et al., 2015) and normalized using gene therapy. Correction of c-met, MMP-10, and cathepsin F levels in diabetic limbal epithelial cultures by AV-driven gene transfer was able to accelerate scratch wound healing and increase putative LESC marker expression (Kramerov, Ghiam, & Ljubimov, 2017) . This therapy was also effective when the virus was substituted by a cell-targeted nanopolymer (Kramerov, Gangalum, Ding, Ljubimova, & Ljubimov, 2016) . Another way of normalizing diabetic corneal epithelial progenitor cells would be to generate autologous induced pluripotent stem cells and differentiate them to limbal cells for transplantation. Although these studies have just begun, they may yield in the near future promising candidates for autologous cell therapy effective against diabetic keratopathy. Similar strategies could be also used to normalize stromal and endothelial diabetic corneal cells.
Conclusions and perspectives
Diabetic corneal disease is a significant clinical problem affecting over a half of diabetic population. However, it is not receiving proper attention from physicians and remains underdiagnosed and underestimated. Clinical manifestations are variable and mainly concern epithelial problems (the most salient being slow and incomplete wound healing) neuropathy (loss of corneal sensation and possibility of developing neurotrophic ulcers), and tear film. A number of molecular alterations have been documented in the diabetic corneas including basement membrane changes, dysfunctional stem cells, altered profiles of growth factors, cytokines, and miRNAs, and accumulation of AGEs. The mainstream therapy remains symptomatic, although some promising therapeutic candidates have recently emerged. Topical insulin, and an FDAapproved opioid antagonist naltrexone appear to be ready for clinical use due to their safety and efficacy. They were also shown to alleviate symptoms of both neuropathy and keratopathy, which is an obvious advantage. Other treatments including autologous serum, thymosin b 4 and some growth factors are still being exam-ined for efficacy. A drawback in preclinical testing of new drugs is the predominant use of animals with IDDM (Table 3) , although the majority of human diabetics have NIDDM. For this reason, the use of human corneal organ cultures may be advantageous, as they seem to reflect the ratio between diabetes types more correctly. Another unresolved issue is a potential difference in corneal changes depending on the type of diabetes, which should be examined in future studies. New promising approaches involving gene, nano, and cell therapy, are currently at fairly early preclinical stages. The development of new biological treatments that would counteract both keratopathy and neuropathy in the diabetic cornea is much needed to alleviate consequences of ulcerations, as well as of laser treatment for PDR and refractive surgeries. It may be anticipated that therapy for major abnormalities of corneal epithelium, nerves, and tear film would require a combination of several drugs for most efficacy, similar to modern cancer treatment.
